SoundHound Inc.’s Houndify Voice AI Powers In-Car Assistant in Honda’s Newest European Models
SoundHound Inc. Ⓡ the leading innovator of voice-enabled AI and conversational intelligence technologies, today announced a milestone in its strategic partnership with Honda Motor Company with the integration of its Houndify voice AI platform into the new Honda e electric car and the top selling Honda Jazz in Europe. The Honda Personal Assistant—powered by Houndify—gives drivers an in-car conversational interface allowing them to control their environment, while accessing navigation, entertainment, and information hands-free. The personal assistant supports five major European languages.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200827005197/en/
New Honda e and Jazz Cars in Europe to Feature In-Car Voice Assistant (Photo: Business Wire)
Houndify voice AI includes patented Speech-to-MeaningⓇ and Deep Meaning Understanding™ technologies to deliver unprecedented speed and accuracy in voice recognition and responses. The platform’s ability to understand context, such as the user’s location or previous queries, eliminates the need to repeat information and allows more natural conversations.
Through the power of Houndify’s voice AI, drivers and passengers can ask Honda Personal Assistant even the most complex questions, such as: “OK Honda, show me restaurants within five kilometers, except French and Japanese ones, that have Wi-Fi, have at least three stars, and are open past 10 pm.” Houndify’s ability to remember context allows for useful follow-up questions, such as “Does it have parking?” The natural language interface can proactively prompt for the next step, like directions to the destination. Deep navigation integration allows drivers to further the experience by asking questions such as, “Are there any convenience stores along the way?”
“Honda e is the first fully electric vehicle to feature Houndify’s voice AI platform, and Jazz is one of Honda’s most popular cars in Europe , ” said Keyvan Mohajer, CEO and co-founder of SoundHound Inc. “We are proud of our partnership with Honda Motor Company and look forward to the growing use of the Honda Personal Assistant in Europe.”
SoundHound Inc. and Honda Motor Company first announced their partnership in October 2018 and premiered their collaboration at the 2019 Tokyo Motor show, where they demonstrated the Honda Personal Assistant to positive reviews.
The voice-enabled Honda Personal Assistant is available on Honda e and select Honda Jazz models in French, German, Spanish, Italian, and English languages.
To learn more about Honda Personal Assistant, powered by Houndify, visit SoundHound Inc.’s Speech-to-Meaning blog.
Developers interested in exploring Houndify’s independent voice AI platform can visit Houndify.com to learn more and register for a free account.
About SoundHound Inc.:
SoundHound Inc. turns sound into understanding and actionable meaning. We believe in enabling humans to interact with the things around them in the same way we interact with each other: by speaking naturally to mobile phones, cars, apps, TVs, smart speakers, and every other part of the emerging ‘connected’ world. Our consumer app, Hound, leverages our Speech-to-MeaningⓇ and Deep Meaning Understanding™ technologies to create a groundbreaking smartphone experience, and is the first product to build on the Houndify platform. Our SoundHound App applies our technology to music, enabling people to discover, explore, and share the music around them, and even find the name of that song stuck in their heads by singing or humming. Through the Houndify platform, we aim to bring voice-enabled AI to everyone and enable others to build on top of it. We call this Collective AI. Our Mission: Houndify everything.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200827005197/en/
Contact information
Michael Zagorsek
SoundHound Inc.
408-441-3270
mike@soundhound.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lazard Appoints Edouard Panié as Managing Director and Co-Head of European Financial Sponsors Coverage20.10.2025 09:00:00 EEST | Press release
Lazard, Inc. (NYSE: LAZ) today announced the appointment of Edouard Panié as Managing Director and Co-Head of the European Financial Sponsors Coverage. He will report to Klaus H. Hessberger, Global Co-Head and Head of Europe for Lazard’s Financial Sponsors Group, to further strengthen the firm’s presence and partnerships with financial sponsors across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019307537/en/ Edouard Panié Mr. Panié joins from Goldman Sachs, where he was a Managing Director for nearly two decades, advising on more than 60 landmark M&A, debt, and equity transactions for leading alternative asset managers in private equity, growth equity, and infrastructure, as well as entrepreneurs, families, and corporates. “Private capital is playing an increasingly pivotal role in shaping industries and driving growth. Edouard’s extensive experience and relationships will strengthen Lazard’s ability to pro
Lone Star Announces Sale of Xella to Holcim20.10.2025 07:40:00 EEST | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund X, LP of a binding agreement to sell Xella Group (“Xella”), a leading provider of walling solutions, to Holcim, the leading partner for sustainable construction. The transaction values Xella at approximately €1.85 billion. Headquartered in Duisburg, Germany, Xella is a European provider of efficient and sustainable walling solutions for the entire house shell, operating brands such as Ytong, Silka, Hebel and Multipor. The company employs more than 4,000 team members. In partnership with Lone Star, Xella has taken significant strides in recent years to optimize its offering by strategically focusing the business on walling solutions, while also enhancing its commercial and digital capabilities. Under Lone Star’s stewardship, Xella has also continued to progress its sustainability initiatives. Today, the business stands as a market leader in its sector with a strong reputation for a people-first c
Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products20.10.2025 07:00:00 EEST | Press release
Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the market introduction of several additions to its MOSS!MODULARITY™ platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019799867/en/ MOSS!MODULARITY Injection Screw MOSS!MODULARITY encompasses a broad range of products and technologies for spinal surgery based around the concept of providing an advanced modular workflow for posterior stabilization and deformity correction. The modular workflow allows surgeons to place the headless bone screw shafts as a first step, without the tulip heads attached, and offers several advantages over working with traditional pre-assembled pedicle screws, e.g.: Improved visualisation and access to the surgical working space; Precise decompression, decortication and osteotomies without any interference with polyaxial tulip heads; Increased surgic
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom